Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't think it's fluff news, but it's not a major catalyst at this point. Long term, it could be significant, as COVID is pretty much with us for good.
Looking forward to another weekly update from Eric. Hopefully, there's more meat on the bones this time.
This is what concerns me. Even if they were to just get the past due 2019 filings in order, it would be a huge relief.
On the plus side, CBBT his not involved with any scammy COVID technologies, which seem to be another main driver for SEC suspensions (CO*UV, DE*CN, several others). And in fact, CBBT via PKG is manufacturing a FDA approved mask for COVID, so that is a plus.
That's exactly what I've heard too, from the EN*ZC board. @GodfatherCap on Twitter, who is on top of everything EN*ZC related, has posted some incredible info re: Jane
Interesting, they also recently showed up for EN*ZC
Busy day at work, more so than usual. Definitely happy to see this north of .10 once again. Would feel better if we stayed north of .20
Good morning
When Eric stated in December that the deal was closing in, I figured mid February was realistic. Nothing gets done in December, and January has everyone scrambling to catch up on all the tasks which were left behind as a result of Holiday Brain.
Now, I'm hopeful for a Sprint time surprise...fingers crossed for confirmation by the week of March 23rd.
Yep, holding pattern until either we get a substantial update, or holders grow weary and start selling.
TAB - Got it, thanks!
Fingers crossed that CBBT joins PU*GE and EN*ZC in the esteemed ranks of OTC/pink stocks that follow through on their promises to investors.
OK good, phew!
Hopefully it's not the SEC locking us out.
https://www.pkguis.com/what-we-do
Founded in 1989 with only three employees, PKG began its success with the design and manufacture of full-travel keyboards and other custom user interfaces. By the early 1990's, PKG shifted its focus to manufacturing membrane switches and user interface sub-assemblies. With a strong engineering team and persistent emphasis on R&D, PKG grew rapidly in the user interface industry.
Now, located near Boise, Idaho - a known hotbed for leading-edge technology companies - in a state of the art facility, PKG partners with a variety of companies to provide high-end user interface solutions for Medical, Industrial, Government, and Aerospace industries.
They are not a package company, wrong PKG.
I agree with this, and am happy to see the update. What I do find a bit concerning, is that he is just now hiring additional hands to help with the filings. What was overlooked, or unearthed during NMS' audit, that they are just now dealing with?
I believe that rising interest rates are playing a role in this, too.
Yeah, this is pretty incredible. OTC market bubble is deflating.
What was the claim in the post you replied to, it was deleted.
CBBT, red today, like most OTC tickers.
The Kloudgaze acquisition is off. They are now acquiring Smart Axiom.
https://www.smartaxiom.com
Of course. Can you share the link?
I'm bullish on EXROF in the same way I was bullish on PLUG in 2014.
Beers For Tears. Now I need to hear some 80's tunes.
Doubtful. I'll go with the first day of Spring, just cause it sounds neat.
CBBT is NOT Caveat Emptor on OTCMarkets. CBBT has a working website, phone number, social media, and they have an Investor Relations Department which is responsive.
SEC has been cracking down on tickers that are CE, and are either the subject of coordinated social media pumps, or have no obvious operations.
There are doubts, of course. This deal is taking way longer than any of us expected. And Eric would have been wise to follow the old adage of 'under promise and over deliver'.
But those saying that CBBT is a ripe target for the SEC are wrong.
CBBT is NOT Caveat Emptor on OTCMarkets. CBBT has a working website, phone number, social media, and they have an Investor Relations Department which is responsive.
You can see the latest SEC trading suspensions here: https://www.sec.gov/litigation/suspensions.htm
Check those tickers on OTCMarkets and you'll see the trend.
Doubtful. SEC is cracking down on Caveat Emptor tickers that several years overdue on filings, that have been getting pumped via social media, and which largely are for businesses that are totally dark (no working website, phone, e-mail, etc.).
Where does it show that Intel holds CBBT shares?
This I agree with. Can anyone provide a reason why financial filings haven't been done while waiting for the acquisition to finalize? Are there any technicalities associated with the deal that would make doing so impossible, or challenging?
Again, this is very frustrating. But why would Eric open himself up to potential investor fraud allegations by tweeting these updates? He has repeatedly stated that the acquisition is a go.
The one thing I wish we had more detail on, is what exactly has led to the delays.
Keep it moving!
Thank you for your concern.
COVID-19 has made business dealing a bit more complicated/tardy.
Overall market is down. OTC is hit with both the overall trend along with the SEC cracking down on Caveat Emptor listings, further spooking investors.
The acquisition is taking longer than anticipated, and that is frustrating. But Eric's continued communication is a big plus.
Yes, more lemons. Plus some sugar. So lemonade, just in time for Spring.
That seems like as reasonable of an assumption as I've yet heard. That said, I do believe Judy Pudy posted some info re: his estate, and that it's been taken care of.
Overview
During the quarter ended, December 31, 2019, the Company continued to position its product, NovaDerm®, to enter clinical trials to gain FDA product approval. Having secured Orphan Drug Designation as a biologic for NovaDerm®, we complied with the FDA annual reporting requirements. In addition, as part of an asset purchase agreement, we granted Amarantus Bioscience Holdings, Inc., a right of first refusal for the purchase of any engineered skin technology designed for treatment of severe burns in humans that we developed. This right of first refusal expired during this quarter on November 7, 2019.
Recently, the risk of introducing pathogens when using materials from animals to produce drugs, devices, and biologics has increased awareness of the safety issues. NovaDerm® and future Regenicin products use animal sourced materials like collagen to produce the life-saving products. We have worked with our collagen supplier and the FDA to ensure we are meeting the expectations for traceability and purity of the FDA for NovaDerm® production. We have arranged for sufficient Bovine Closed Herd corium to produce sufficient collagen scaffolds to meet our needs for the clinical trials, ensuring compliance with FDA requirements.
Our major objective for 2021 is to secure the required funding to finalize some additional requirements of the IND application and begin the clinical trials. As previously reported, our goal in obtaining the required funding has been to minimize shareholders’ dilution as much as possible. Consequently, we are primarily pursuing financing through the issuance of debt instruments, international licensing agreements and governmental grants. We have completed all the administrative requirements to allow us to apply for grants. Regenicin is now registered with System For Award Management (“SAM”) which is required to do business with the US Government. We must have our IND submitted before we can request financial assistance from The US FDA Office of Orphan Products Clinical Trials Grant. We intend to take full advantage of working with OOPD to develop our clinical protocol according to suggestions from the FDA during our Pre-IND meeting.
The Orphan Drug Act created the Orphan Product Grants Program, which is administered by OOPD, to stimulate the development of promising products for rare diseases and conditions. Orphan product grants are a proven method of fostering and encouraging the development of new safe and effective medical products for rare diseases and conditions. These grants support new and continuing extramural research projects that test the safety and efficacy of promising new drugs, biologics, devices, and medical foods through human clinical trials in very vulnerable populations often with life-threatening conditions.
Here's their most recent filing: https://yahoo.brand.edgar-online.com/DisplayFiling.aspx?TabIndex=2&dcn=0001662252-21-000007&nav=1&src=Yahoo